FREDUN PHARMACEUTICALS LIMITED

Compassionate Healthcare

CIN No: L24239MH1987PLC043662



FREDUN PHARMACEUTICALS LTD.

UNAUDITED FINANCIAL RESULTS (PROVISIONAL) FOR THREE MONTHS ENDED

30 Jun 17

	DIDTICIII ADC	Quarter ended			Year ended
10	PARTICULARS		31.03.2017	30.06.2016	31.03.2017
		30,06,2017 (Unaudited)	(Audited)	(Unaudited)	(Audited)
1	Income from Operations			1610.00	7//0//0
	Net Sales /IncomeFrom Operation (Net of Excise Duty)	914.94	1735.65	1649.90	5669.62
2	Other Operating Income	15.33	31.40	17.57	191.38
3	Total income from operatoins (net)	930.27	1767.05	1667.47	5861.00
4	Expenses	17797821 2721		200 20	2205.05
	a) Cost of Material Consumed	704.44	891.98	809.22	3395.85
	b) Purchases of stock -in-trade	0.00	0.00	0.00	23.68
	c) Changes in inventories of finished goods, work-in-progress and stock in trade	(119.24)		426.58	298.35
	d)Finance Costs	36.11	60.87	37.90	187.48
	e) Employess benefits expenses	96.26	152.31	99.57	491.82
	f) Depreciation and amortisation expenses	22.39	48.19	20.11	113.58
	g) Other Expenses	145.28	327.64	198.37	1125.26
	Total Expenditure	885.24	1656.34	1591.75	5636.02
5	Profit/(Loss) from ordinary activities before exceptional items & tax (3+4)	45.03	110.71	75.72	224.98
6	Exceptional items / Prior Period Item	0.00	0.00	0.00	(2.39
7	Profit/(Loss) from ordinary activities before tax (5-6)	45.03	110.71	75.72	222.59
8	Tax Expenses	8.00	67.85	15.00	79.8
9	Profit/(Loss) from continuing operations	37.03	42.86	60.72	142.7
10	Profit/(Loss) from discontinued operations	0.00	0.00	0.00	0.0
11	Tax Expense of discontinued operations	0.00	0.00	0.00	0.0
12	Profit/(Loss) from discontinued operations after tax	0.00	0.00	0.00	0.0
13	Profit/ (Loss) for the period	37.03	42.86	60.72	142.7
14	Other comprehensive Income				
14	A (i) Items that will not be re-classified to profit/ loss	0.00	0.00	0.00	0.0
	(ii) Income tax relating to items that will not be re-classified to profit/ loss	0.00	0.00	0.00	0.0
	B (i) Items that will be re-classified to profit / loss	0.00	0.00	0.00	0.0
	(ii) Income tax relating to items that will be re-classified to profit/ loss	0.00	0.00	0.00	0.0
15	Paid up Equity Share Capital (Face Value of Rs-10/- each)	237.45	237.45	237.45	237.4
16	Reserves excluding Revaluation Reserves	0.00	0.00	0.00	238.5
17	Earning per Share (EPS) for continuing operations - Basic	1.56	1.81	2.56	6.0
17	- Diluted	1.56	4.37	2.56	6.1
	Earning per Share (EPS) for discontinuing operations - Basic	0.00	0.00	0.00	0.0
	- Diluted	0.00	0.00	0.00	0.0
	Earning per Share (EPS) for continuing and discontinuing operations - Basic	1.56	1.81	2.56	6.0
	- Diluted	1.56	4.37	2.56	6.1
	Basic/ Diluted Earning Per Share (Rs.) (for continuing and discontinued operations)		30. 1773. 1774. 1775. 1775. 1775. 1775. 1775. 1775. 1775. 1775. 1775. 1775. 1775. 1775. 1775. 1775. 1775. 1775	2.56	6.0
Α.		112.			
A	Number of shares	60129	0 60129		
	Percentage of shareholding	25.5	6 25.5	6 25.56	25.5
	Promoters and promotor group shareholding				
	a) Pledged/Encumbured	1	1		
	- Number of shares	i-	•	13	1 -
	- Percentage of shares (as a % of total shareholding of Promoters and Prompter Group)	-	-] [
	- Percentage of shares (as a % of total share capital of the Company)	-		1	asset.
	b) Non-encumbered	175111	0 175111	0 1751110	17511
	- Number of shares	100		[[다] [[다] [[다] [[다] [[다] [[다] [[다] [[다]	59 E TO 10 10 10 10 10 10 10 10 10 10 10 10 10
1	 Percentage of shares (as a % of total shareholding of Promoters and Prompter Group) Percentage of shares (as a % of total share capital of the Company) 	74.4	950		

- 1) The above results were taken on record by the Board Of Directors at the meeting held on 11.08.2017
- 2) Previous year's figures have been regrouped/rearranged wherever necessary.
- 3) During the quarter ended 30th June 2017 there are no investor's complaints pending & no investor's complaints were received by the company during this period.
- 4) Provision for deferred tax as applicable will be made at the end of the year
- 5) Dividend on Preference shares will be considered at the year end.
- 6) The above result have already been approve by the Audit Comittee of the board

Office Address: Manoj Industrial Premises, G.D.Ambekar Marg, Wadala, Mumbai – 400 031, (INDIA) Phone: 91-22 — 4031 8111 Fax: 91-22-40318133 E-mail: business@fredungroup.com Web: www.fredungroup.com

Factory Address: 14,15,16, Zorabian Industrial Complex, Veoor, Palghar (E), Dist: Palghar - 401 404.

Phone: 91-2525-253194 Fax No: 91-2525-253193

FREDUN PHARMACEUTICALS LIMITED

Compassionate Healthcare

CIN No: L24239MH1987PLC043662

7) This statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable. Beginning 1st April 2017, the Company has for the first time adopted Ind AS with a transition date of 1st April, 2016.

ployee Benefit Expense				Rs. in Lacs
Particulars	30.06.2017 (Unaudited)	Quarter ended 31.03.2017 (Audited)	30.06.2016	Year ended 31.03.2017 (Audited)
Salary & Wages	75.29	119.05	74.93	
Director Remuneration	12.30	12.30	12.30	
Contributionn to Provident and Other Funds	4.06	9.99	3.34	
Share Base Payment to employees	0.00	0.00	0.00	
Staff Welfare Expenses	2.74	5.37	3.34	17.52

9) Gain/ Loss on account of Foreign Exchange Fluctuation (Included in other Income)	Rs. in Lacs				
Particulars		Quarter ended		Year ended	
rancuais	30.06.2017	31.03.2017	30.06.2016	31.03.2017	1
	(Unaudited)	(Audited)	(Unaudited)	(Audited)	
Gain / Loss on Account of Foreign Exchange	0.78	6.73	0.00		6.73

10) Reconciliation of Net Profit between Previous GAAP and IND AS

Rs. in Lacs

	Quarter ended	30.06.2017	
7	I- GAAP	Effect of transition to IND AS	IND -AS
Income from Operations			
Net Sales /IncomeFrom Operation (Net of Excise Duty)	914.94	-	914.94
Other Operating Income	15.33		15.33
Total income from operatoins (net)	930.27		930.27
Expenses			ma
a) Cost of Material Consumed	704.44		704.44
b) Purchases of stock -in-trade	0.00		0.00
c) Changes in inventories of finished goods, work-in-progress and stock in trade	(119.24)	127	(119.24
d)Finance Costs	36.11	-	36.11
e) Employess benefits expenses	96.26		96.26
f) Depreciation and amortisation expenses	22.39	1	22.39
g) Other Expenses	145.28	-	145.28
Total Expenditure	885.24	170	885.24
Profit/(Loss) from ordinary activities before exceptional items & tax (3+4)	45.03	0320	45.03
Exceptional items / Prior Period Item	0.00		0.00
Profit/(Loss) from ordinary activities before tax (5-6)	45.03		45.03
Tax Expenses	8.00	-	8.00
Profit/(Loss) from continuing operations	37.03	(37.03
Profit/(Loss) from discontinued operations	0.00	-	0.00
Tax Expense of discontinued operations	0.00	-	0.00
Profit/(Loss) from discontinued operations after tax	0.00	-	0.0
Profit/ (Loss) for the period	37.03	-	37.03
Other comprehensive Income	0.00		0.0
Total Comprehensive Income for the period	37.03		37.0

PLACE: MUMBAI

DATE: 11.08.2017

FOR FREDUN PHARMACEUTICALS LIMITED

DIRECTOR.

Office Address: Manoj Industrial Premises, G.D.Ambekar Marg, Wadala, Mumbai – 400 031, (INDIA)
Phone: 91-22 – 4031 8111 Fax: 91-22-40318133 E-mail: business@fredungroup.com Web: www.fredungroup.com

Factory Address: 14,15,16, Zorabian Industrial Complex, Veoor, Palghar (E), Dist: Palghar - 401 404.

Phone: 91-2525-253194 Fax No: 91-2525-253193